ArticleBiomimetics (Basel, Switzerland)2026
Contact Lenses Incorporating Methotrexate-Loaded Chitosan/Hyaluronic Acid Nanoparticles.
Article in Biomimetics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Nanoparticle-laden contact lenses (CLs) represent a promising strategy for ocular drug delivery. Nanocarriers built from hyaluronic acid and chitosan offer a biomimetic alternative to synthetic polymers, by combining the lubricating property of hyaluronic acid with the mucoadhesive property of chitosan. However, achieving sustained drug release without compromising lens properties remains challenging, and the influence of lens material and replacement modality is unclear. This study evaluated methotrexate (MTX)-loaded chitosan/hyaluronic acid (CS/HA) nanoparticles incorporated into silicone hydrogel CLs with different replacement modalities, assessing their effect on drug release kinetics. Daily replacement lenses (Senofilcon A and Delefilcon A) released 26 ± 4% and 33 ± 5% of MTX after 24 h, respectively. The monthly lens Lehfilcon A showed slower diffusion-controlled release, with only 15 ± 2% released at 24 h and a 64 ± 3% cumulative release after 31 days (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.